Drugs.com - Clinical Trials

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Alterity Therapeutics Announces Positive ATH434 Phase 2...

Feb 9, 2025 0

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 January 2025: Alterity Therape...

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Zydus Announces USFDA Orphan Drug Designation to Usnofl...

Feb 9, 2025 0

Ahmedabad, India, January 22, 2025 Zydus, a leading, discovery-based, global pha...

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune Announces U.S. FDA Breakthrough Therapy Des...

Feb 9, 2025 0

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January...

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Merck Announces Phase 3 waveLINE-010 Trial Initiation E...

Feb 9, 2025 0

RAHWAY, N.J.--(BUSINESS WIRE) February 6, 2025 -- Merck (NYSE: MRK), known as M...

Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease

Genentech’s Phase IIb Study of Prasinezumab Missed Prim...

Feb 9, 2025 0

South San Francisco, CA -- December 18, 2024 -- Genentech, a member of the Roche...

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Concept Achieved In Cardiovascular Disease Study

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Co...

Feb 9, 2025 0

Malmö, Sweden 18 December 2024 PILA PHARMA AB (publ) (“PILA PHARMA” or the “Comp...

LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus

LimmaTech Awarded FDA Fast Track Designation for Vaccin...

Feb 9, 2025 0

SCHLIEREN, Switzerland--(BUSINESS WIRE)-- December 19, 2024 LimmaTech Biologics ...

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

Vertex Announces Results From Phase 2 Study of Suzetrig...

Feb 9, 2025 0

BOSTON--(BUSINESS WIRE)--Dec. 19, 2024-- Vertex Pharmaceuticals Incorporated (Na...

$Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia$

Nurix Therapeutics Receives U.S. FDA Fast Track Designa...

Feb 9, 2025 0

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasda...

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)

Sapience Therapeutics Receives FDA Orphan Drug Designat...

Feb 9, 2025 0

TARRYTOWN, N.Y., December 19, 2024 – Sapience Therapeutics, Inc., a clinical-sta...

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Po...

Feb 9, 2025 0

DALLAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Gradalis Inc., a clinical-stage biotec...

NIH Researchers Discover Novel Class of Anti-Malaria Antibodies

NIH Researchers Discover Novel Class of Anti-Malaria An...

Feb 9, 2025 0

January 3, 2025 -- A novel class of antibodies that binds to a previously untarg...

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics Announces Successful Completion and...

Feb 9, 2025 0

NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: A...

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight in the REDEFINE 1 Trial

CagriSema Demonstrates Superior Weight Loss in Adults w...

Feb 9, 2025 0

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline resu...

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Mineralys Therapeutics Announces Phase 2 Clinical Trial...

Feb 9, 2025 0

RADNOR, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nas...

Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery

Vergent Bioscience Receives FDA Fast Track Designation ...

Feb 9, 2025 0

MINNEAPOLIS, Minn., January 7, 2025 – Vergent Bioscience, a clinical-stage biote...

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Announces Positive Topline Results From Phase...

Feb 9, 2025 0

SAN DIEGO – January 10, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) to...

Research and Pipeline Research Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Research and Pipeline Research Pfizer’s Sasanlimab in C...

Feb 9, 2025 0

NEW YORK--(BUSINESS WIRE)-- January 10, 2025 -- Pfizer Inc. (NYSE: PFE) today a...

Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis

Nipocalimab Granted U.S. FDA Priority Review for the Tr...

Feb 9, 2025 0

SPRING HOUSE, Pa., (January 9, 2025) – Johnson & Johnson (NYSE: JNJ) today annou...

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

Johnson & Johnson’s Posdinemab and Tau Active Immunothe...

Feb 9, 2025 0

TITUSVILLE, N.J., January 8, 2025 -- Johnson & Johnson (NYSE: JNJ) announced tod...

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics Announces Additional FDA Fast Trac...

Feb 9, 2025 0

CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (...

Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function

Humanetics Corporation Announces Positive Phase 2 Clini...

Feb 9, 2025 0

MINNEAPOLIS, MN -- January 22, 2025 -- Humanetics Corporation (Humanetics) annou...

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Announces FDA Has Lifted the Cli...

Feb 9, 2025 0

CAMBRIDGE, Mass.-- January 21, 2025 (BUSINESS WIRE)-- Amylyx Pharmaceuticals, I...

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics Receives FDA Fast Track Designation f...

Feb 9, 2025 0

WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasda...

3
4
5
6

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.